Phaseline

Targets › SOD3

SOD3 (Extracellular superoxide dismutase [Cu-Zn]): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Jan 2027.

Secreted antioxidant enzyme that acts as the primary scavenger of superoxide radicals in the extracellular space, converting them to hydrogen peroxide and thereby protecting tissues from oxidative damage. Also preserves nitric oxide bioavailability by preventing the formation of harmful peroxynitrite. (UniProt, P08294)

Open in Phaseline: the race on SOD3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
West China Hospitalsuperoxide dismutase skin spray
antioxidant enzyme that catalyzes the dismutation of superoxide radicals
SOD1, SOD2, SOD3Phase 2Radiation-induced DermatitisJan 2027

Conditions

Radiation-induced Dermatitis (1)

Modalities

protein or peptide (1)

Companies

West China Hospital (1)

Related targets

SOD1 (1) SOD2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.